Goldman Sachs Group Inc Summit Therapeutics Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
Call Options
2 transactions
Others Institutions Holding SMMT
# of Institutions
266Shares Held
90.9MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$737 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$190 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$173 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$87.8 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$85.4 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.4B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...